01 July 2020
Visiongain has launched a new pharma report Clinical Perinatal Software Market Report 2020-2030: Forecasts by Type (Care Collaboration Solutions (Medication Administration Solutions, Perinatal Care Management Solutions, Rounding Solutions, Other Care Collaboration Solutions), Data Integration Solutions (EMR Integration Solutions, Medical Image Integration Solutions), Enterprise Reporting & Analytics Solutions, Real-Time Communication Solutions (Nurse Call Alert Systems, Unified Communication Solutions), Workflow Automation Solutions (Nursing & Staff Scheduling Solutions, Patient Flow Management Solutions)), End User (Ambulatory Care Centers, Long-Term Care Facilities, Hospitals), and Geography (North America, Latin America, Europe, Asia Pacific, MEA).
The global clinical perinatal software market is anticipated to grow at a lucrative CAGR of ~xyz% and anticipated to reach USD xyz billion by 2020. Visiongain anticipates that the market will grow on account of growing birth rates coupled with the rising number of post-date pregnancy.
To access the data contained in this document please email firstname.lastname@example.org
Various research studies are currently underway, which are expected to create a competitive advantage for manufacturers to develop new and innovative and advanced software that is expected to provide a variety of additional opportunities in the perinatal clinical software market. The market growth is nevertheless to be restricted with the high costs of perinatal software and a strict legal framework.
Prenatal clinical software provides information to doctors and patients about their healthcare and the safety of their fetuses, i.e., (pregnant women). This software helps collect preventive information about complications or complexity during pregnancy.
Advancements and development of software services for clinical perinatal applications is expected to positively affect the growth of the market
High levels of adoption of healthcare IT services due to the resulting efficiency of work and ease of operations with its application; this factor is expected to drive the growth of the market
The requirement of large capital funding and investments for the adoption and integration of these software products; this factor is expected to restrain the growth of the market. Lack of knowledge and skillsets in professionals and physicians that cause complications and complexities in operating the software; this factor is expected to restrain the market growth.
North America dominated the global clinical perinatal software market owing to developed healthcare infrastructure coupled with well-developed healthcare IT sector. Also, the market will continue to be driven by the existence of the target population and increased R&D investment by important business organizations. Asia Pacific region is expected to experience the highest growth in terms of CAGR over the forecast period owing to the growing presence of cancer cases in markets such as India and China. Additionally, unmet needs of patients and untapped nations in this region have been attracting investments by global players and this is expected to boost the clinical perinatal software market growth over the forecast period.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global clinical perinatal software market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the clinical perinatal software market.
For instance, In February 2020, Cerner Corporation agreed with Intermountain Healthcare, this agreement mainly focuses to expand the two organizations’ longstanding commitment for initiation enhancing the experience, quality, and safety of health care for patients and caregivers. This agreement was also engaged in finding a new way of advancing the practice of medicine to improve patient care. By entering into such an innovative agreement, the company enhanced its credibility in the market by serving a large patients base.
The comprehensive market report features companies such as Airstrip Technologies, Inc, AS Software Inc., Cerner Corporation, Clinical Computer Systems, Inc., CliniComp International, Cognitive Medical Systems, EdanUSA, Epic Systems Corporation, Gaumard Scientific, GE Healthcare, Harmony Healthcare IT, Huntleigh Healthcare Limited, K2 Medical Systems Ltd, Koninklijke Philips N.V., Medical Information Technology, Inc., Meridian Health Informatics, PeriGen, Inc., Trium Analysis Online GmbH among other prominent players. Also, the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.
26 November 2020
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth